Product Reports Resources Pricing Login Book a demo

Bluebird bio

Biotech & Life Sciences · Cambridge, United States · Founded 1993 · IPO 2013

Integrated product platforms encompass gene therapy, cancer immunotherapy and gene editing

Valuation $150M
Revenue $84M
Power Law Thoroughbred$100M+ revenue

Investors

12 investors on Bluebird bio's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series B+ 12 investors entered at this stage
Third Rock Ventures
Sanofi Ventures
Forbion Capital Partners
California Institute for Regenerative Medicine
TVM Capital Life Science
Techno Venture Management
ARCH Venture Partners
RA Capital Management
Massachusetts Institute of Technology
Deerfield Partners
Sanofi-Genzyme BioVentures
Whitehead Institute

Bluebird bio mafia

Startups founded by Bluebird bio alumni

Former Bluebird bio employees who went on to start their own companies. Sorted by Dealroom signal score.

Umoja BiopharmaEst. 2019
Andy ScharenbergUnited States
Signal score88
Kelonia TherapeuticsEst. 2020
Kevin FriedmanUnited States
Signal score84
EmphereEst. 2025
Ankit KumarUnited States
Signal score74
Generation BioEst. 2016
MAMark D. AngelinoUnited States
Signal score62
OncorusEst. 2015
Cyrus MozayeniUnited States
Signal score62
Chameleon BiosciencesEst. 2017
Genine WInslowUnited States
Signal score56
Epigene LabsEst. 2019
Akpeli NordorFrance
Signal score51
Luna GeneticsEst. 2018
Philip ReillyUnited States
Signal score45

Book a demo to explore the full alumni network →

Global footprint

Where Bluebird bio has talent and traffic

Workforce by country
13 countries with
team presence
🇺🇸 United States93.5%
🇫🇷 France1.3%
🇿🇦 South Africa0.9%
🇮🇳 India0.9%
🇧🇷 Brazil0.5%
Top 5 of 13 shown
Web traffic by country
3.2K monthly visits
across markets
🇮🇳 India56.3%
🇺🇸 United States40.6%
Top 2 markets shown

Talent graph

The shape of Bluebird bio's talent

Dealroom maps Bluebird bio's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

7 standout operatorsDealroom-flagged across the org
2 AI specialistsincl. 1 core researchers
308 employees mappedperson by person
DimensionScore
AI Talentlive Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock Bluebird bio's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$100M patent portfolio · 43 active families

Estimated portfolio value
$100M
66.4% of market cap · 1.7× larger than top peer TP Therapeutics ($60M)
43 active patent families
Where Bluebird bio innovates Autoimmune conditionAutoimmune diseaseCancer researchCarcinosisCell

Where Bluebird bio concentrates vs peers

Each axis is a top-10 topic across Bluebird bio and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Bluebird bio

An AI-synthesized read of the highest-engagement posts about Bluebird bio on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Bluebird bio on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles